A5059544350- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- HIV/AIDS drug development and treatment
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Memory and Neural Mechanisms
- Neuroscience and Neuropharmacology Research
- RNA Interference and Gene Delivery
- Synthesis and Biological Evaluation
- Neuroinflammation and Neurodegeneration Mechanisms
- T-cell and B-cell Immunology
- Peptidase Inhibition and Analysis
- Cellular transport and secretion
- Calcium signaling and nucleotide metabolism
- CAR-T cell therapy research
- Chemokine receptors and signaling
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Cancer Research and Treatments
- Animal Genetics and Reproduction
- Click Chemistry and Applications
- Musicology and Musical Analysis
- HIV Research and Treatment
- Dendrimers and Hyperbranched Polymers
- Neurogenesis and neuroplasticity mechanisms
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2024
Fred Hutch Cancer Center
2024
Cancer Consortium
2023
Baylor College of Medicine
2021-2022
Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression DNA accessibility revealed that genes encoding these functional proteins correlated with BATF motif accessibility. IFN-γ + effectively killed myeloma comparable efficacy transitory effectors, disease...
<p>PK parameter estimates for the nirogacestat dose-effect model</p>
<p>Visual predictive checks for the nirogacestat dose effect PK model by dose</p>
<p>mbBCMA density in MM cells after 24-hour exposure to nirogacestat and other GSIs</p>
<p>Summary of adverse events</p>
<p>Comparison of BCMA density (MESF) between CD19- and CD19+ plasma cells in bone marrow (baseline post-dose samples combined)</p>
<p>Nirogacestat pharmacokinetic model diagnostic plots</p>
<p>Nirogacestat treatment decreases sBCMA concentration</p>
<p>Parameter estimates for the BCMA PKPD model</p>
<p>Participant demographics and baseline characteristics</p>
<p>PKPD model diagnostic plots</p>
<p>Visual predictive checks of the nirogacestat-BCMA PKPD model by dose</p>
<p>Isolation of BCMA-expressing PCs in whole blood and bone marrow</p>
<p>Comparison of BCMA density (MESF) between CD19- and CD19+ plasma cells in bone marrow (baseline post-dose samples combined)</p>
<p>mbBCMA density in MM cells after 24-hour exposure to nirogacestat and other GSIs</p>
<p>PK parameter estimates for the nirogacestat dose-effect model</p>
<p>Summary of adverse events</p>
<p>Visual predictive checks of the nirogacestat-BCMA PKPD model by dose</p>
<p>Isolation of BCMA-expressing PCs in whole blood and bone marrow</p>
<p>Nirogacestat treatment decreases sBCMA concentration</p>
<p>Participant demographics and baseline characteristics</p>
<p>Visual predictive checks for the nirogacestat dose effect PK model by dose</p>
<p>PKPD model diagnostic plots</p>
<p>Parameter estimates for the BCMA PKPD model</p>
<p>Nirogacestat pharmacokinetic model diagnostic plots</p>